Pioneering the third generation of probiotics
Probiotics engineered for specific medical conditions.
Pioneering the third generation of probiotics
Probiotics engineered for specific medical conditions.
Our mission is to engineer safe and affordable probiotics to manage specific medical conditions.
The Evolution of Probiotics
First-generation probiotics were derived from food, supporting general gut health. The bioinformatics revolution gave rise to second-generation probiotics—strains linked to health benefits. However, their effects were largely associative, with limited testing in humans and unclear impact on specific diseases.
Today, Concordance is pioneering third-generation probiotics—engineered for precise, mechanism-driven effects with efficacy validated in human clinical studies.
NSAIDs and gastrointestinal toxicity
Innovative Biotechnology Solutions at Concordance Therapeutics
Our gastrointestinal tract is lined by a complex barrier that protects the body. This barrier relies on healthy epithelial cells, mucus production, and a balanced gut microbiome.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used medications worldwide. While effective for pain and inflammation, they disrupt gut integrity by inhibiting prostaglandin synthesis, weakening mucosal defenses, increasing intestinal permeability, and altering the gut microbiome.
In the United States alone, tens of millions of people use NSAIDs daily. NSAIDs are essential medicines, but their widespread use raises a critical question: how can we protect the gut while preserving their benefits?
About CTX-101
CTX101 is an engineered probiotic designed for use alongside NSAIDs. It is being developed as a medical food for the dietary management of NSAID-associated disruption to gut integrity and function.
The product is built on a food-grade probiotic with a history of safe use in humans, and is already manufactured commercially.
Updates
Concordance Wins Silicon Valley Bank-Babson Pitch Competition!
CEO Justin Hayes Presents at Microbiome Times Summit in Brussels
Concordance Wins Silicon Valley Bank-Babson Pitch Competition!
Concordance Moves into The Engine!
CEO Justin Hayes Presents at Microbiome Times Summit in Brussels
Concordance Wins Silicon Valley Bank-Babson Pitch Competition!
CEO Justin Hayes Presents at Microbiome Times Summit in Brussels
CEO Justin Hayes Presents at Microbiome Times Summit in Brussels
CEO Justin Hayes Presents at Microbiome Times Summit in Brussels